AI Article Synopsis
- Myelofibrosis is a disease where the body makes too many stem cells, leading to issues like anemia and enlarged organs.
- This review talks about new treatments for anemia in myelofibrosis, including different types of medicine that help fight the disease.
- Experts say that current treatments don't work very well and can be harmful, but new drugs are showing better results and can help patients improve.
Article Abstract
Introduction: Myelofibrosis is a clonal myeloproliferative neoplasm associated with the proliferation of hematopoietic stem cells, increased bone marrow fibrosis, extramedullary hematopoiesis, hepatosplenomegaly, abnormal cytokine production, and constitutional symptoms. These and many other factors contribute to the development of anemia in myelofibrosis patients.
Areas Covered: This review summarizes novel and promising treatments for anemia in myelofibrosis including transforming growth factor-β inhibitors luspatercept and KER-050, JAK inhibitors momelotinib, pacritinib, and jaktinib, BET inhibitors pelabresib and ABBV-744, antifibrotic PRM-151, BCL2/BCL-XL inhibitor navitoclax, and telomerase inhibitor imetelstat.
Expert Opinion: Standard approaches to treat myelofibrosis-related anemia have limited efficacy and are associated with toxicity. New drugs have shown positive results in myelofibrosis-associated anemia when used alone or in combination.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/13543784.2023.2294324 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!